PRAX

Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc. (PRAX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Profitability (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.8 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -33.5
EV / EBITDA -20.7
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -12.8%
Price Return 12M 78.7%
Catalyst Signal 0.00
Market Cap $9.2B
TTM Revenue N/A
Price / Sales N/A
ROE -44.8%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C+ (2.8) D (1.3) C (2.2) C+ (2.6) C (2.3)
2026-11-07 C+ (2.5) B- (3.0) D (1.4) C (2.3) C+ (2.7) C (2.4)
2026-10-31 C+ (2.5) B- (2.9) D (1.4) C+ (2.7) C+ (2.7) C (2.4)
2026-10-24 C+ (2.5) C+ (2.8) D (1.4) C (2.3) C+ (2.6) C (2.3)
2026-10-17 C+ (2.5) B- (2.9) D (1.4) C (2.4) C+ (2.6) C (2.4)
Page 1 of 5